1 From Roswell Park Cancer Institute; Dana-Farber/Brigham and Women’s Cancer Center; Duke Cancer Institute; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Huntsman Cancer Institute at the University of Utah; Memorial Sloan-Kettering Cancer Center; Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; Prostate Health Education Network; University of Washington/Seattle Cancer Care Alliance; Fox Chase Cancer Center; City of Hope Comprehensive Cancer Center; Massachusetts General Hospital Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; Vanderbilt-Ingram Cancer Center; University of Michigan Comprehensive Cancer Center; Moffitt Cancer Center; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center; UCSF Helen Diller Family Comprehensive Cancer Center; The University of Texas MD Anderson Cancer Center; Patient Advocate; Stanford Cancer Institute; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; and National Comprehensive Cancer Network.
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.